About Dapagliflozin (Propanediol Monohydrate) API
Therapeutic Category 抗糖尿病
CAS Number
461432-26-8
API Technology
Synthetic
Dose Form
Lotion (Topical)
Dr Reddy's Development Status
Available
Available Regulatory Filing
Singapore DMF, Europe (CEP)
Mechanism of Action
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion
Indication
FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
エンパグリフロジン
抗糖尿病
シタグリプチン塩酸塩（ 一水和物）
抗糖尿病
シタグリプチンリン酸エステル（無水物）
抗糖尿病
シタグリプチン塩酸塩（ 一水和物
抗糖尿病
Semaglutide
抗糖尿病
ピオグリタゾン塩酸塩
抗糖尿病
ダパグリフロジン（非晶質）
抗糖尿病
ダパグリフロジン（プロ パンジオール一水和物）
抗糖尿病
グリメピリド
抗糖尿病
リナグリプチン（AB型）
抗糖尿病
リラグルチド
抗糖尿病